Skip to main content

Table 1 Patient characteristics before and after matching

From: Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis

Covariates

Before matching

After matching

Photon

n = 349

Proton

n = 64

p

SMD

Photon

n = 55

Proton

n = 55

p

SMD

Age, years (mean (SD))

60.38 (11.91)

65.53 (13.29)

0.002

0.408

62.27 (11.79)

63.90 (13.14)

0.495

0.131

Sex (%)

  

0.024

0.287

  

0.303

0.198

 Male

292 (83.7)

46 (71.9)

  

48 (87.3)

44 (80.0)

  

 Female

57 (16.3)

18 (28.1)

  

7 (12.7)

11 (20.0)

  

Histology (%)

  

0.867

0.207

  

1.000

0.067

 Well differentiated

7 (2)

0 (0)

  

0 (0.0)

0 (0.0)

  

 Moderately differentiated

58 (16.6)

10 (15.6)

  

7 (12.7)

7 (12.7)

  

 Poorly differentiated

24 (6.9)

5 (7.8)

  

4 (7.3)

5 (9.1)

  

 Not available

260 (74.5)

49 (76.6)

  

44 (80.0)

43 (78.2)

  

AJCC stage (%)

  

< 0.001

0.782

  

0.913

0.081

 I/II

32 (9.2)

26 (40.6)

  

18 (32.7)

17 (30.9)

  

 III

279 (79.9)

33 (51.6)

  

31 (56.4)

33 (60.0)

  

 IVA

38 (10.9)

5 (7.8)

  

6 (10.9)

5 (9.1)

  

Liver Fibrosis Score (%)

  

< 0.001

0.712

  

0.829

0.041

 Ishak F1–4

51 (14.6)

16 (25.0)

  

14 (25.5)

15 (27.3)

  

 Ishak F5–6

231 (66.2)

48 (75.0)

  

41 (74.5)

40 (72.7)

  

 Not available

67 (19.2)

0 (0)

  

0 (0.0)

0 (0.0)

  

Hepatitis B (%)

  

0.001

0.663

  

0.920

0.077

 Negative

107 (30.7)

25 (39.1)

  

18 (32.7)

20 (36.4)

  

 Positive

166 (47.6)

38 (59.4)

  

36 (65.5)

34 (61.8)

  

 Missing

76 (21.8)

1 (1.6)

  

1 (1.8)

1 (1.8)

  

Hepatitis C (%)

  

0.001

0.633

  

0.914

0.082

 Negative

197 (56.4)

43 (67.2)

  

40 (72.7)

38 (69.1)

  

 Positive

81 (23.2)

20 (31.2)

  

14 (25.5)

16 (29.1)

  

 Missing

71 (20.3)

1 (1.6)

  

1 (1.8)

1 (1.8)

  

Alpha-Fetoprotein (%)

  

< 0.001

0.719

  

0.701

0.073

 < =200 ng/mL

127 (36.4)

35 (54.7)

  

30 (54.5)

32 (58.2)

  

 > 200 ng/mL

155 (44.4)

29 (45.3)

  

25 (45.5)

23 (41.8)

  

 Missing

67 (19.2)

0 (0)

  

0 (0)

0 (0)

  

ALBI Grade (%)

  

< 0.001

0.610

  

0.604

0.192

 1

80 (22.9)

24 (37.5)

  

21 (38.2)

20 (36.4)

  

 2

231 (66.2)

24 (37.5)

  

26 (47.3)

23 (41.8)

  

 Missing

38 (10.9)

16 (25.0)

  

8 (14.5)

12 (21.8)

  

Child-Pugh class (%)

  

< 0.001

0.876

  

0.757

0.193

 A

204 (58.5)

59 (92.2)

  

51 (92.7)

51 (92.7)

  

 B

68 (19.5)

4 (6.2)

  

2 (3.6)

4 (7.3)

  

 C

4 (1.1)

0 (0.0)

  

0 (0.0)

0 (0.0)

  

 Missing

73 (20.9)

1 (1.6)

  

2 (3.6)

1 (1.8)

  

Tumor number (%)

  

0.157

0.229

  

0.741

0.198

 Single

128 (36.7)

26 (40.6)

  

21 (38.2)

21 (38.2)

  

 Multiple

213 (61.0)

34 (53.1)

  

33 (60.0)

31 (56.4)

  

 Missing

8 (2.3)

4 (6.2)

  

1 (1.8)

3 (5.5)

  

Size of the largest tumor (%)

  

0.270

0.305

  

0.809

0.125

 < =5 cm

97 (27.8)

24 (37.5)

  

19 (34.5)

17 (30.9)

  

 > 5 and < =10 cm

132 (37.8)

23 (35.9)

  

22 (40.0)

21 (38.2)

  

 > 10 cm

111 (31.8)

17 (26.6)

  

14 (25.5)

17 (30.9)

  

 Missing

9 (2.6)

0 (0.0)

  

0 (0.0)

0 (0.0)

  

PVTT (%)

  

< 0.001

0.922

  

0.669

0.199

 Absent

66 (18.9)

36 (56.2)

  

28 (50.9)

28 (50.9)

  

 Present

275 (78.8)

24 (37.5)

  

26 (47.3)

24 (43.6)

  

 Missing

8 (2.3)

4 (6.2)

  

1 (1.8)

3 (5.5)

  
  1. AJCC American Joint Committee on Cancer, ALBI Albumin-bilirubin, PVTT Portal vein tumor thrombosis, SMD Standardized mean difference